A new oral kallikrein inhibitor for long‐term prophylaxis of hereditary angioedema

Hereditary angioedema (HAE) is a rare inherited chronic disease characterisedby unpredictable recurrent attacks of cutaneous and submucosal swelling potentially involving airways, frequently upper ones,and compromising patient's life. This impliesa serious health problem with significant burden reduced life quality(1). presentsa great clinical variability different endotypes,hampering diagnosis requiring personalised treatment. The primary mediator in most phenotypes bradykinin,which increasesvasodilation vascular permeability by binding to the bradykinin B2 receptor (2). In Type 1 2 HAE, C1-INH leads deficiency contact (kallikrein-kinin) system activation bradykininoverproduction (2, 3).Early andappropriate therapy are essential due itsunpredictability, life-threatening nature,and unresponsiveness conventional emergency therapies (adrenaline, corticosteroids,or antihistamines)(1). Specific on-demand products for acute management focus on replacing plasma-derived C1 inhibitor recombinant human inhibitor, inhibiting (icatibant), or inactivating plasma kallikrein (ecallantide).